Not provided
Not provided
Not provided
Not provided
Not provided
Due to high mortality
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Endoscopic Variceal Ligation | Experimental | Endoscopic Variceal Ligation every 3 weeks till eradication |
|
| Carvedilol | Active Comparator | Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Endoscopic Variceal Ligation | Procedure | Endoscopic Variceal Ligation every 3 weeks till eradication. |
|
| Measure | Description | Time Frame |
|---|---|---|
| First Variceal Bleeding | 1.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Death | 1.5 years | |
| Procedure related complications. | 1.5 years | |
| Reappearance of Esophageal varices in presence of Portal Vein Thrombosis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dr Shakti P Choudhury, MD | Institute of Liver and Biliary Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Liver and Biliary Sciences | New Delhi | National Capital Territory of Delhi | 110070 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Carvedilol | Drug | Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD |
|
| 1.5 years |
| ID | Term |
|---|---|
| D000077261 | Carvedilol |
| ID | Term |
|---|---|
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D002227 | Carbazoles |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D006575 | Heterocyclic Compounds, 3-Ring |
Not provided
Not provided